Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Schaeverbeke

Showing results (1-10 of 182) with videos related to

Pageof 19
Sort By:
Presse Medicale (Paris, France : 1983)|March 23, 2010
[Osteoarticular manifestations of Gaucher's Disease and imiglucerase efficacy on bone mineral density in adults. Review of literature]Thierry Schaeverbeke
Annals of the Rheumatic Diseases|March 24, 2021
Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'Marc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|March 15, 2018
Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and BennuciMarc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|January 6, 2019
'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?Marc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|January 28, 2018
Response to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and BenucciMarc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|July 29, 2018
Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon <i>et al</i>Marie Kostine, Thierry Schaeverbeke,
Annals of the Rheumatic Diseases|August 14, 2018
Response to: 'Checkpoint inhibitors and arthritis: seeking balance between victories and defeats' by Moura and MouraThierry Schaeverbeke, Marie Kostine
Arthritis & Rheumatology (Hoboken, N.J.)|July 31, 2018
ReplyMarie-Elise Truchetet, Thierry Schaeverbeke
The Journal of Rheumatology|April 1, 2005
Infliximab induced chilblain lupus in a patient with rheumatoid arthritisChristophe Richez, Chantal Dumoulin, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|June 22, 2018
Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and BassMarie Kostine, Léa Dousset, Thierry Schaeverbeke, et al.
Pageof 19

Showing results (1-10 of 182) with videos related to

Sort By:
Pageof 19
Presse Medicale (Paris, France : 1983)|March 23, 2010
[Osteoarticular manifestations of Gaucher's Disease and imiglucerase efficacy on bone mineral density in adults. Review of literature]Thierry Schaeverbeke
Annals of the Rheumatic Diseases|March 24, 2021
Correspondence on 'Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting'Marc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|March 15, 2018
Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and BennuciMarc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|January 6, 2019
'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?Marc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|January 28, 2018
Response to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and BenucciMarc Scherlinger, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|July 29, 2018
Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon <i>et al</i>Marie Kostine, Thierry Schaeverbeke,
Annals of the Rheumatic Diseases|August 14, 2018
Response to: 'Checkpoint inhibitors and arthritis: seeking balance between victories and defeats' by Moura and MouraThierry Schaeverbeke, Marie Kostine
Arthritis & Rheumatology (Hoboken, N.J.)|July 31, 2018
ReplyMarie-Elise Truchetet, Thierry Schaeverbeke
The Journal of Rheumatology|April 1, 2005
Infliximab induced chilblain lupus in a patient with rheumatoid arthritisChristophe Richez, Chantal Dumoulin, Thierry Schaeverbeke
Annals of the Rheumatic Diseases|June 22, 2018
Response to: 'Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor' by Chan and BassMarie Kostine, Léa Dousset, Thierry Schaeverbeke, et al.
Pageof 19